| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
Y 27632 di hydrochloride
|
129830-38-2 |
Y27632 (HYDROCHLORIDE)
|
Y-27632二盐酸盐, 一种选择性ROCK1(P160ROCK)抑制剂;反式-4-[(R)-1-氨基乙基]-N-(4-吡啶基)环己烷甲酰胺二盐酸盐
|
C14H23Cl2N3O |
320.25792 | 813-428-5 |
|
2-[[2-Ethoxy-4-(4-hydroxy-1-piperidinyl(phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one
|
1234480-50-2 |
2-[[2-乙氧基-4-(4-羟基-1-哌啶基)苯基]氨基]-5,11-二氢-5,11-二甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮
|
2-[[2-乙氧基-4-(4-羟基-1-哌啶基)苯基]氨基]-5,11-二氢-5,11-二甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮;CS-641
|
C26H30N6O3 |
475 | |
|
XMD17-109
|
1435488-37-1 |
11-环戊基-2-[[2-乙氧基-4-[[4-(4-甲基-1-哌嗪基)-1-哌啶基]羰基]苯基]氨基]-5,11-二氢-5-甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮
|
11-环戊基-2-[[2-乙氧基-4-[[4-(4-甲基-1-哌嗪基)-1-哌啶基]羰基]苯基]氨基]-5,11-二氢-5-甲基-6H-嘧啶并[4,5-B][1,4]苯并二氮杂卓-6-酮;XMD17 109;XMD17109;CS-1288
|
C36H46N8O3 |
638.80224 | |
|
Cabozantinib malate
|
1140909-48-3 |
苹果酸卡博替尼(CABOZANTINIB S-MALATE)
|
XL184;XL-184;CABOZANTINIB;XL 184;CABOZANTINIB (S)-苹果酸盐;N-[4-[(6,7-二甲氧基-4-喹啉基)氧基]苯基]-N'-(4-氟苯基)-1,1-环丙烷二甲酰胺 (S)-苹果酸盐;CABOZANTINIB MALATE;卡博替尼苹果酸盐;苹果酸卡博替尼;苹果酸盐;L-苹果酸卡博替尼
|
C32H30FN3O10 |
635.5931032 | 691-711-0 |
|
XEN445
|
1515856-92-4 |
(S)-2-(3-(PYRIDIN-2-YLMETHOXY)PYRROLIDIN-1-YL)-5-(TRIFLUOROMETHYL)BENZOIC ACID. HCL
|
XEN 445;XEN-445;(S)-2-(3-(PYRIDIN-2-YLMETHOXY)PYRROLIDIN-1-YL)-5-(TRIFLUOROMETHYL)BENZOIC ACID. HCL;2-[(3S)-3-(2-吡啶基甲氧基)-1-吡咯烷基]-5-(三氟甲基)苯甲酸;CS-1251
|
C18H17F3N2O3 |
366.3343896 | |
|
XAV 939
|
284028-89-3 |
3,5,7,8-四氢-2-[4-(三氟甲基)苯基]-4H-噻喃并[4,3-D]嘧啶-4-酮
|
3,5,7,8-四氢-2-[4-(三氟甲基)苯基]-4H-噻喃并[4,3-D]嘧啶-4-酮;3,8-四氢-2-[4-(三氟甲基)苯基]-4H-硫代吡喃并[4,3-D]嘧啶-4-酮;CS-300;XAV-939;XAV 939;一种选择性的WNT通路Β-CATENIN介导的转录抑制剂
|
C14H11F3N2OS |
312.31015 | 687-302-1 |
|
WS6
|
1421227-53-3 |
N-(6-(4-(2-(4-((4-METHYLPIPERAZIN-1-YL)METHYL)-3-(TRIFLUOROMETHYL)PHENYLAMINO)-2-OXOETHYL)PHENOXY)PYRIMIDIN-4-YL)CYCLOPROPANECARBOXAMIDE
|
|
C29H31F3N6O3 |
568.5900496 | |
|
WS3
|
1421227-52-2 |
N-(6-(4-(3-(4-((4-METHYLPIPERAZIN-1-YL)METHYL)-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)PYRIMIDIN-4-YL)CYCLOPROPANECARBOXAMIDE
|
重复
|
C28H30F3N7O3 |
569.5781096 | |
|
WP1066
|
857064-38-1 |
(2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基乙基]-2-丙烯酰胺
|
(2E)-3-(6-溴-2-吡啶基)-2-氰基-N-[(1S)-1-苯基乙基]-2-丙烯酰胺;WP1066,一种新型的JAK2和STAT3抑制剂;WP1066;WP 1066;WP-1066
|
C17H14BrN3O |
356.21656 | |
|
Wnt-C59-C59
|
1243243-89-1 |
1G;5G;1G;25G;5G
|
WNT C59;C59;WNTC59;CS-876;4-(2-甲基-4-吡啶基)-N-[4-(3-吡啶基)苯基]苯乙酰胺;2-(4-(2-甲基吡啶-4-基)苯基)-N-(4-(吡啶-3-基)苯基)乙酰胺;2-[4-(4-(2-甲基吡啶)苯基]-N-(4-(3-吡啶)苯基)-乙酰胺;WNT-C59 (C59);WNT C59;C59;WNT-C59,一种有效的PORCN 酶活性和 WNT抑制剂
|
C25H21N3O |
379.45374 | |
|
WHI-P180
|
211555-08-7 |
3-[(6,7-二甲氧基-4-喹唑啉基)氨基]苯酚
|
3-[(6,7-二甲氧基-4-喹唑啉基)氨基]苯酚>98%;3-[(6,7-二甲氧基-4-喹唑啉基)氨基]苯酚
|
C16H15N3O3 |
297.3086 | |
|
WHI-P154
|
211555-04-3 |
2-溴-4-(6,7-二甲氧基喹唑啉-4-基氨基)苯酚
|
CS-1516;2-溴-4-(6,7-二甲氧基喹唑啉-4-基氨基)苯酚;4-(3'-溴-4'-羟基苯基)氨基-6,7-二甲氧基喹唑啉
|
C16H14BrN3O3 |
376.20466 | 809-014-9 |
|
JANEX-1
|
202475-60-3 |
4-(4'-羟基苯基)氨基-6,7-二甲氧基喹唑啉
|
4-(4'-羟基苯基)氨基-6,7-二甲氧基喹唑啉>98%;WHIP-131;JANEX-1);WHIP131;JANEX1;4-(4'-羟基苯基)氨基-6,7-二甲氧基喹唑啉;JANEX-1;WHI-P131
|
C16H15N3O3 |
297.31 | |
|
WH-4-023
|
837422-57-8 |
2,6-DIMETHYLPHENYL 2,4-DIMETHOXYPHENYL(2-(4-(4-METHYLPIPERAZIN-1-YL)PHENYLAMINO)PYRIMIDIN-4-YL)CARBAMATE
|
2,6-二甲基苯基 N-[2,4-二(甲氧基)苯基][2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基甲酸酯;DUAL LCK/SRC INHIBITOR;KIN001-112; KIN112
|
C32H36N6O4 |
568.68 | |
|
VX 702
|
745833-23-2 |
6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺
|
2-(2,4-二氟苯基)-6-(1-[2,6-二氟苯基)脲基]烟酰胺;6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺;VX702;VX-702
|
C19H12F4N4O2 |
404.317793 | |
|
Tozasertib
|
639089-54-6 |
陶扎色替
|
N-[4-[[4-(4-甲基-1-哌嗪基)-6-[(5-甲基-1H-吡唑-3-基)氨基]-2-嘧啶基]硫]苯基]环丙烷甲酰胺;陶扎色替;VX680;MK0457;VX 680 (MK 0457;TOZASERTIB);TOZASERTIB;MK-0457;MK0457;VX680;VX 680;MK 0457;陶扎色替VX-860;VX-680;MK-0457,陶扎色替;陶扎色替TOZASERTIB;CS-177
|
C23H28N8OS |
464.59 | |
|
VX-661
|
1152311-62-0 |
1-(2,2-二氟-1,3-苯并二氧戊环-5-基)-N-[1-[(2R)-2,3-二羟基丙基]-6-氟-2-(2-羟基-1,1-二甲基乙基)-1H-吲哚-5-基]-环丙烷甲酰胺
|
VX 661;VX661;VX-661;VX 661;VX661;VX-661;TEZACAFTOR;CS-956;1-(2,2-二氟-1,3-苯并二氧戊环-5-基)-N-[1-[(2R)-2,3-二羟基丙基]-6-氟-2-(2-羟基-1,1-二甲基乙基)-1H-吲哚-5-基]-环丙烷甲酰胺
|
C26H27F3N2O6 |
520.4975896 | |
|
Vortioxetine hydrobromide
|
960203-27-4 |
氢溴酸沃替西汀
|
1-[2-(2,4-二甲基苯硫基)苯基]哌嗪氢溴酸盐;沃替西汀氢溴酸盐(LUAA21004);溴酸沃替西汀;氢溴酸沃泰西汀;沃替西汀氢溴酸;4-[-2-(2,4-二甲基-苯硫烷基)-苯基-哌嗪氢溴酸盐
|
C18H23BRN2S |
378.08 | |
|
Vortioxetine
|
508233-74-7 |
沃替西汀
|
伏硫西汀;沃替丁汀;4-[-2-(2,4-二甲基-苯硫烷基)-苯基-哌嗪;沃赛汀杂质;伏氧西汀;沃替西汀碱;沃替西汀对照品;1-[2-(2,4-甲基苯硫基)苯基]哌嗪;沃替西汀
|
C17H17N3O |
279.34 | |
|
Vitamin E
|
59-02-9 |
天然维生素 E
|
维生素E胶丸;维生素E油;天然维生素 E;[2R-[2R*(4R*,8R*)]]-3,4-二氢-2,5,7,8-四甲基-2-(4,8,12-三甲基十三烷基)-6-色满醇;(+;-)-[2R*(4R*,8R*)]-3,12-三甲基十三烷基)-6-色满醇;维他命 E;维生素E;天然维生素E;生育酚;维他命 E;[2R-[2R*(4R*,12-三甲基十三烷基)-6-色满醇;(+)-5,8-三甲基母育酚;2,8-四甲基-2-(4',8',12'-三甲基十三烷基)-6-色满醇醋酯;维他命戊;VE;D-ALPHA-生育酚;D-ALPHA-维生素E
|
C29H50O2 |
430.71 | 215-798-8 |
药智官方微信
药智官方微博
